Polycythemia Vera Pipeline Booms with Over 20 Companies and 25+ Drugs in Development

Polycythemia Vera Pipeline Expands with Over 20 Companies and 25+ Drugs in Development

The Polycythemia Vera pipeline is a rapidly growing landscape, with over 20 companies and 25+ drugs currently in development. The disease, which involves uncontrolled red blood cell production, has no cure and treatment goals are focused on symptom relief and reducing the risk of complications.

Merck Sharp & Dohme LLC's bomedemstat (MK-3543) is the most advanced drug candidate in the pipeline, currently in Phase III development. Bomedemstat is an investigational small molecule that inhibits LSD1, a key player in myeloproliferative neoplasms.

Other notable candidates include Flonoltinib, developed by Chengdu Zenitar Biomedical Technology, and PRT12396 from Prelude Therapeutics. Both drugs are designed to target the JAK2V617F mutation, which is present in over 90% of Polycythemia Vera patients.

The report provides a comprehensive overview of the Polycythemia Vera pipeline, including clinical trials, route of administration, and molecule type. The analysis highlights the importance of targeting the JAK2 pathway in the treatment of this disease.